Abstract
Objective:
Radioimmunotherapy of cancer with radiolabeled antibodies has shown promise. We evaluated an anti-CD25 monoclonal Antibody, 7G7/B6, armed with 90Y as a potential radioimmunotherapeutic agent for CD25-expressing lymphomas.
Materials and Methods:
The lymphoma model was established by subcutaneous injection of 1 × 107 SUDHL-1 cells into nude mice. The biodistribution of 111In-7G7/B6 and therapeutic studies with 90Y-7G7/B6 were performed in the tumor-bearing mice.
Results:
Therapy using 90Y-7G7/B6 prolonged survival of the SUDHL-1 lymphoma-bearing mice significantly, as compared with either untreated mice or the mice treated with 90Y-11F11, a radiolabeled isotype-matched control antibody (p < 0.001). All of the mice in the control and the 90Y-11F11 treatment groups died by days 18 and 24, respectively. In contrast, 30% of the mice in the low-dose group (75 μCi of 90Y-7G7/B6/mouse) and 75% in the high-dose group (150 μCi of 90Y-7G7/B6/mouse) became tumor free and remained healthy for greater than 6 months.
Conclusions:
Our findings suggested that 90Y-7G7/B6 is a potentially useful radioimmunotherapeutic agent for the treatment of patients with CD25-expressing lymphomas.